Hydroxyurea safety study for young children with sickle cell
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has sickle cell anemia (HbSS or HbS/B0-thalassemia).
- Your child is between 6 months and 12 years old when the study starts.
- A parent or guardian can sign consent and follow study instructions.
- Your child must weigh at least 7.5 kg at enrollment (if not, they may be delayed).
- If your child took hydroxyurea in the last 6 months, they usually cannot join right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This study looks at how people of Nigerian descent with sickle cell disease respond to hydroxyurea, a medicine that helps prevent painful episodes. The goal is to see how your genetic makeup affects how the drug works so that doctors can find the best dose for you.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
This study looks back at past pregnancy and breastfeeding experiences in women with sickle cell disease who took hydroxyurea. It aims to better understand how hydroxyurea exposure may affect pregnancy and baby outcomes.
Hear when a new Sickle Cell Anemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.